{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:15:22Z","timestamp":1761743722031,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jaci.2012.11.021","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T08:02:10Z","timestamp":1356163330000},"page":"117-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biologics and the treatment of chronic rhinosinusitis"],"prefix":"10.1016","volume":"131","author":[{"given":"Robert C.","family":"Kern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2012.11.021_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2012.11.021_bib3","first-page":"1","article-title":"The European position paper on rhinosinusitis and nasal polyps","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"key":"10.1016\/j.jaci.2012.11.021_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0091-6749(99)70118-1","article-title":"Eosinophilic airway inflammation in nasal polyposis","volume":"104","author":"Lamblin","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2500\/aap.2012.33.3599","article-title":"Omalizumab: an update on safety and efficacy in moderate to severe asthma","volume":"33","author":"Chipps","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2012.11.021_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1081-1206(10)60184-6","article-title":"Baseline characteristics of patients enrolled in EXCELS: a cohort study","volume":"103","author":"Long","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2010.02.026","article-title":"What targeting eosinophils has taught us about their role in diseases","volume":"126","author":"Bochner","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.med.58.061705.145252","article-title":"Does anti-IgE therapy help in asthma? Efficacy and controversies","volume":"58","author":"Avila","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2012.11.021_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2012.02.046","article-title":"Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps","volume":"130","author":"Takabayashi","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2012.11.021_bib13","series-title":"Eosinophils in health and disease","article-title":"Eosinophils in CRS","author":"Schleimer","year":"2012"},{"key":"10.1016\/j.jaci.2012.11.021_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674912018362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674912018362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:38:23Z","timestamp":1758789503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674912018362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0091674912018362"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2012.11.021","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and the treatment of chronic rhinosinusitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2012.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}